Company news

Addex Therapeutics Ltd news in 2026

Addex Therapeutics Ltd's news releases, calls and decks from 2026, newest first.

View company

Addex Therapeutics Announces Executive Management Changes

October 2, 2026

Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update

September 28, 2026

Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior

September 25, 2026

Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026

September 24, 2026

ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027

August 26, 2026

Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness

July 8, 2026

Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

June 25, 2026

Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026

June 22, 2026

Invitation (432)

June 5, 2026

Addex Convenes Annual General Meeting 2026

June 5, 2026

Addex Reports Full Year 2025 Financial Results and Provides Corporate Update

April 30, 2026

Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model

April 29, 2026

Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026

April 23, 2026

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

April 21, 2026

Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment

February 3, 2026

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia

January 7, 2026

Calls in 2026

Decks in 2026